Advances in modern immunology in infectious diseases, allergic diseases, tumors, and neurological disorders

doi:10.3969/j.issn.1006-7795.2023.02.001

Abstract

Abstract:

Immunology, as an interdisciplinary subject, involves a variety of subjects and many aspects of different diseases. For the past few years, many breakthroughs have been made in basic and clinical research of immunology, which has deepened the understanding of immunological response and its regulatory mechanism in many common diseases. These findings provide a new scientific basis and clinical means of prevention and treatment for the pathogenesis of immune-related diseases. In this review, we focus on the key cells and important signaling pathways in immunology, and the role of cytokines in infectious diseases, allergic diseases, tumors and neurological disorders.

Key words: infectious diseases, allergic diseases, tumor, neurological diseases, immunity

CLC Number:

R392

Chen Yan, Zhang Xulong, Xu Jiangnan, Jia Yufeng, Sun Ying. Advances in modern immunology in infectious diseases, allergic diseases, tumors, and neurological disorders[J]. Journal of Capital Medical University, 2023, 44(2): 179-185.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2023.02.001

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2023/V44/I2/179

References

［1］Wu X, Yao D D, Bao L L, et al. Ficolin A derived from local macrophages and neutrophils protects against lipopolysaccharide-induced acute lung injury by activating complement［J］. Immunol Cell Biol, 2020, 98(7):595－606.
［2］Wu X, Bao L L, Hu Z Q, et al. Ficolin A exacerbates severe H1N1 influenza virus infection-induced acute lung immunopathological injury via excessive complement activation［J］. Cell Mol Immunol, 2021, 18(9):2278－2280.
［3］Ren X W, Wen W, Fan X Y, et al. COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas［J］. Cell, 2021, 184(7):1895－1913.e19.
［4］Liao M F, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19［J］. Nat Med, 2020, 26(6):842－844.
［5］Melms J C, Biermann J, Huang H C, et al. A molecular single-cell lung atlas of lethal COVID-19［J］. Nature, 2021, 595(7865):114－119.
［6］Wang L, Wen M Y, Cao X T. Nuclear hnRNPA2B1 initiates and amplifies the innate immune response to DNA viruses［J］. Science, 2019, 365(6454):eaav0758.
［7］Solis A G, Bielecki P, Steach H R, et al. Mechanosensation of cyclical force by PIEZO1 is essential for innate immunity ［J］. Nature, 2019, 573(7772):69－74.
［8］Xu X L, Han M F, Li T T, et al. Effective treatment of severe COVID-19 patients with tocilizumab［J］. Proc Natl Acad Sci U S A, 2020, 117(20):10970－10975.
［9］Liu B, Bao L L, Wang L, et al. Anti-IFN-γ therapy alleviates acute lung injury induced by severe influenza A (H1N1) pdm09 infection in mice［J］. J Microbiol Immunol Infect, 2021, 54(3):396－403.
［10］Liu S, Li H, Wang Y M, et al. High expression of IL-36γ in influenza patients regulates interferon signaling pathway and causes programmed cell death during influenza virus infection［J］. Front Immunol, 2020, 11:552606.
［11］Xue C X, Wen M J, Bao L L, et al. Vγ4+γδT cells aggravate severe H1N1 influenza virus infection-induced acute pulmonary immunopathological injury via secreting interleukin-17A［J］. Front Immunol, 2017, 8:1054.
［12］Zhou Z W, He H B, Wang K, et al. Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells［J］. Science, 2020, 368(6494):eaaz7548.
［13］Yao D D, Bao L L, Li F D, et al. H1N1 influenza virus dose dependent induction of dysregulated innate immune responses and STAT1/3 activation are associated with pulmonary immunopathological damage［J］. Virulence, 2022, 13(1):1558－1572.
［14］Van De Veerdonk F L, Giamarellos-Bourboulis E, Pickkers P, et al. A guide to immunotherapy for COVID-19［J］. Nat Med, 2022, 28(1):39－50.
［15］Sánchez-Borges M, Martin B L, Muraro A M, et al. The importance of allergic disease in public health: an iCAALL statement［J］. World Allergy Organ J, 2018, 11(1):8.
［16］Loftus P A, Wise S K. Epidemiology of asthma［J］. Curr Opin Otolaryngol Head Neck Surg, 2016, 24(3):245－249.
［17］Huang K W, Yang T, Xu J Y, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study［J］. Lancet, 2019, 394(10196):407－418.
［18］Cheng L, Chen J J, Fu Q L, et al. Chinese society of allergy guidelines for diagnosis and treatment of allergic rhinitis［J］. Allergy Asthma Immunol Res, 2018, 10(4):300－353.
［19］Goksr E, Loid P, Alm B, et al. The allergic march comprises the coexistence of related patterns of allergic disease not just the progressive development of one disease［J］. Acta Paediatr, 2016, 105(12):1472－1479.
［20］Murrison L B, Brandt E B, Myers J B, et al. Environmental exposures and mechanisms in allergy and asthma development［J］. J Clin Invest, 2019, 129(4):1504－1515.
［21］Rutkowski K, Sowa P, Rutkowska-Talipska J, et al. Allergic diseases: the price of civilisational progress［J］. Postepy Dermatol Alergol, 2014, 31(2):77－83.
［22］Agache I, Akdis C A. Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases［J］. J Clin Invest, 2019, 129(4):1493－1503.
［23］Li Y, Chen S H, Chi Y F, et al. Kinetics of the accumulation of group 2 innate lymphoid cells in IL-33-induced and IL-25-induced murine models of asthma: a potential role for the chemokine CXCL16［J］. Cell Mol Immunol, 2019, 16(1):75－86.
［24］Gasser P, Eggel A. Targeting IgE in allergic disease［J］. Curr Opin Immunol, 2018, 54: 86－92.
［25］Pitlick M M, Pongdee T. Combining biologics targeting eosinophils (IL-5/IL-5R), IgE, and IL-4/IL-13 in allergic and inflammatory diseases［J］. World Allergy Organ J, 2022, 15(11):100707.
［26］Shankar A, McAlees J W, Lewkowich I P. Modulation of IL-4/IL-13 cytokine signaling in the context of allergic disease［J］. J Allergy Clin Immunol, 2022, 150(2):266－276.
［27］Parnes J R, Molfino N A, Colice G, et al. Targeting TSLP in asthma［J］. J Asthma Allergy, 2022, 15: 749－765.
［28］Ahmadzadeh M, Johnson L A, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired［J］. Blood, 2009, 114(8):1537－1544.
［29］Goronzy J J, Weyand C M. Mechanisms underlying T cell ageing［J］. Nat Rev Immunol, 2019, 19(9):573－583.
［30］Wherry E J. T cell exhaustion［J］. Nat Immunol, 2011, 12(6):492－499.
［31］Miller B C, Sen D R, Al Abosy R, et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade［J］. Nat Immunol, 2019, 20(3):326－336.
［32］Chihara N, Madi A, Kondo T, et al. Induction and transcriptional regulation of the co-inhibitory gene module in T cells［J］. Nature, 2018, 558(7710):454－459.
［33］Wu T Q, Ji Y, Moseman E A, et al. The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness［J］. Sci Immunol, 2016, 1(6):eaai8593.
［34］Teijeira A, Garasa S, Etxeberria I, et al. Metabolic consequences of T-cell costimulation in anticancer immunity［J］. Cancer Immunol Res, 2019, 7(10):1564－1569.
［35］Zappasodi R, Serganova I, Cohen I J, et al. CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours［J］. Nature, 2021, 591(7851):652－658.
［36］Watson M J, Vignali P D A, Mullett S J, et al. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid［J］. Nature, 2021, 591(7851):645－651.
［37］Luoma A M, Suo S B, Williams H L, et al. Molecular pathways of colon inflammation induced by cancer immunotherapy［J］. Cell, 2020, 182(3):655－671.e22.
［38］Bagchi S, Yuan R, Engleman E G. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance［J］. Annu Rev Pathol, 2021, 16: 223－249.
［39］Bailey C M, Liu Y, Liu M Y, et al. Targeting HIF-1α abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues［J］. J Clin Invest, 2022, 132(9):e150846.
［40］Shi K B, Li H D, Chang T, et al. Bone marrow hematopoiesis drives multiple sclerosis progression［J］. Cell, 2022, 185(13):2234－2247.e17.
［41］Tian D C, Zhang C Y, Yuan M, et al. Incidence of multiple sclerosis in China: a nationwide hospital-based study［J］. Lancet Reg Health West Pac, 2020, 1: 100010.
［42］Cavallo S. Immune-mediated genesis of multiple sclerosis［J］. J Transl Autoimmun, 2020, 3:100039.
［43］Liu J W, Liu L, Kang W T, et al. Cytokines/chemokines: potential biomarkers for non-paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis［J］. Front Neurol, 2020, 11:582296.
［44］Han B, Jiang W, Cui P, et al. Microglial PGC-1α protects against ischemic brain injury by suppressing neuroinflammation［J］. Genome Med, 2021, 13(1):47.
［45］Li J J, Zhao X Q, Meng X, et al. High-sensitive C-reactive protein predicts recurrent stroke and poor functional outcome: subanalysis of the clopidogrel in high-risk patients with acute nondisabling cerebrovascular events trial［J］. Stroke, 2016, 47(8):2025－2030.
［46］Meier-Stephenson F S, Meier-Stephenson V C, Carter M D, et al. Alzheimers disease as an autoimmune disorder of innate immunity endogenously modulated by tryptophan metabolites［J］. Alzheimers Dement (N Y), 2022, 8(1):e12283.
［47］Pirooznia S K, Rosenthal L S, Dawson V L, et al. Parkinson disease: translating insights from molecular mechanisms to neuroprotection［J］. Pharmacol Rev, 2021, 73(4):33－97.
［48］Gordon R, Albornoz E A, Christie D C, et al. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice［J］. Sci Transl Med, 2018, 10(465):eaah4066.
［49］Panicker N, Kam T I, Wang H, et al. Neuronal NLRP3 is a parkin substrate that drives neurodegeneration in Parkinsons disease［J］. Neuron, 2022, 110(15):2422－2437.e9.
［50］Walther A, Mackens-Kiani A, Eder J, et al. Depressive disorders are associated with increased peripheral blood cell deformability: a cross-sectional case-control study (Mood-Morph)［J］. Transl Psychiatry, 2022, 12(1):150.
［51］Li Y, Jia Y F, Wang D D, et al. Programmed cell death 4 as an endogenous suppressor of BDNF translation is involved in stress-induced depression［J］. Mol Psychiatry, 2021, 26(6):2316－2333.
［52］Drevets W C, Wittenberg G M, Bullmore E T, et al. Immune targets for therapeutic development in depression: towards precision medicine［J］. Nat Rev Drug Discov, 2022, 21(3):224－244.

[1]	Wang Yi, Ding Yuezhong, Xu Jiangnan. Research progress of follicular helper T cells and their roles in antibody-mediated lung transplant rejection [J]. Journal of Capital Medical University, 2023, 44(2): 186-195.
[2]	Zhang Hanxiao, Duan Luo, Zhang Muzhi, Zhang Ruoyang, Zhao Liuyinuo, Zhou Ruonan, Li Yunqi, Lyu Zhe, Wang Jingjing, Yuan Huihui, Cui Ye, Sun Ying, Wang Wei. Immune characteristics of short-term chronic obstructive pulmonary disease model [J]. Journal of Capital Medical University, 2023, 44(2): 203-211.
[3]	Peng Dan, Pang Jie, Shi Yifan, Cui Lele, Xu Yingjie, Li Yan, Cui Ye, Chen Yan, Yuan Huihui, Qin Xiaofeng, Lyu Zhe, Wang Wei, Sun Ying. Streptococcus pneumoniae infection at early stage of life affect the severity of asthma induced by exposure to the same bacterial antigens in adulthood [J]. Journal of Capital Medical University, 2023, 44(2): 212-220.
[4]	Li Ziyi, Wang Xi, Liang Pu. Progresses on the effect of estrogen on innate immune cells [J]. Journal of Capital Medical University, 2023, 44(2): 351-357.
[5]	Bai Ruojing, Lyu Shiyun, Hua Wei, Wu Hao, Dai Lili. Construction of LILRB2 overexpression lentivirus vector and THP-1-LILRB2 stable transformation cell [J]. Journal of Capital Medical University, 2023, 44(1): 93-98.
[6]	Li Mo, Han Deqiang, Zhao Yu, Chen Zhiguo. Harnessing cell therapy as a therapeutic strategy to fight disease——Professor Chen Zhiguo [J]. Journal of Capital Medical University, 2020, 41(5): 778-782.
[7]	Chen Rongjuan, Chen Qirui, Xu Jiangnan, Ding Yuezhong. Effects to obliterative bronchiolitis by blocking CD40-CD40L pathway in the mouse lung transplantation [J]. Journal of Capital Medical University, 2018, 39(2): 258-264.
[8]	Chen Chen, Meng Yan. Ang Ⅱ activates dendritic cell to produce immune function [J]. Journal of Capital Medical University, 2017, 38(5): 709-714.
[9]	Zhang Yue, Li Yun, Zhu Jinxia, Zhao Wenming. Expression and cellular distribution of dopamine receptors in the rat colonic submucosal plexus [J]. Journal of Capital Medical University, 2017, 38(3): 411-416.
[10]	Yuan Linjie, Chen Shihao, An Gao, Huang Qiong, Yi Dawei, Li Yan, Lyu Zhe, Wang Jingjing, Huang Kewu, Wang Wei, Sun Ying. Changes of immune cells and their subsets in lungs of interleukin (IL)-33-induced allergen-independent murine model of asthma [J]. Journal of Capital Medical University, 2016, 37(5): 561-567.
[11]	Huang Aihua, Zhang Pingping, Zhang Bin, Ma Buqing, Guan Yunqian, Zhou Yidan. Replicative senescence reduced the efficacy of human fetal bone marrow-derived mesenchymal stem cell intravenous treatment of cerebral infarction rats [J]. Journal of Capital Medical University, 2015, 36(6): 865-874.
[12]	Zhao Chunsong, Zou Haiqiang, Yan Xiaoming, Chen Ling, Wang Jiayin, Guan Yunqian, Zhang Y. Alex. Effect of Bmi-1 on apoptosis of human fetal striatum derived neural stem cells [J]. Journal of Capital Medical University, 2015, 36(1): 103-110.
[13]	Feng Xueting, Zhang Chenguang, Zhang Min, Yue Zhixia, Xing Tianyu, Li Shentao, Ding Wei. Application of HaloTag technology in the intracellular imaging and quantitative analysis of alpha-synuclein [J]. Journal of Capital Medical University, 2014, 35(3): 324-330.
[14]	WANG Min, YANG Jun, SHANG Jun, ZHANG Luo. Expression of tumor necrosis factor-α-inducible protein-2 in a mouse model of allergic rhinitis and its relationship with angiogenesis [J]. Journal of Capital Medical University, 2013, 34(6): 790-794.
[15]	LI Xiaobo, GU Jianjuan, ZHAO Chunsong, WANG Shuyan, GUAN Yunqian, CHEN Ling, ZHANG Yu. Lentiviral vector mediated hLPP-3 expression in human umbilical cord derived mesenchymal stem cells [J]. Journal of Capital Medical University, 2013, 34(6): 872-878.